- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Jocelyn Aspa
Jocelyn obtained her diploma in journalism from Langara College in April 2016, just prior to joining INN as a staff writer for the resource sector. Since then, Jocelyn has shifted to covering the life science space and has become managing editor for INN's technology, cannabis and life science divisions. Jocelyn is passionate about niche topics within the life science sector and enjoys shedding light on companies focused on unmet clinical needs.
Prior to joining INN, Jocelyn interned at the Georgia Straight and blogged about the Vancouver Canucks. Before following her career in journalism, Jocelyn spent several years working in law firms. She thrives off the knowledge her background brings to her reporting.
{'community': None}
The Latest Articles From Jocelyn
5 Top NASDAQ Biotech and Pharma Stocks: Neoleukin Up 98 Percent
Dec. 15, 2019 02:55 PM PST
Biotech Trends 2019: M&A Slows, CNS Therapies Make Headlines
Dec. 12, 2019 03:30 PM PST
BioXcel Therapeutics to Expand BXCL701 Study
Dec. 11, 2019 08:54 AM PST
Dare Biosciences and FDA Align on Phase 2b Study Design of Sildenafil
Dec. 11, 2019 08:49 AM PST
Avenue Therapeutics Submits New Drug Application for IV Tramadol
Dec. 11, 2019 08:41 AM PST
MacroGenics Presents Results from SOPHIA Study
Dec. 11, 2019 08:31 AM PST
5 Top Medical Device News Stories of 2019
Dec. 09, 2019 12:50 PM PST
Mustang Bio Announces Additional Clinical Data on MB-107
Dec. 09, 2019 09:37 AM PST
Abeona Therapeutics to Initiate Phase 3 Clinical Trial of B-101
Dec. 09, 2019 09:13 AM PST
Ocugen Completes 50 Percent Enrollment in Phase 3 Clinical Trial
Dec. 09, 2019 09:05 AM PST
Achillion Reports Positive Data from Phase 2 Study of Danicopan
Dec. 09, 2019 08:59 AM PST
Aprea Therapeutics Presents Data from Phase 1b/2 Clinical Trial of APR-246
Dec. 09, 2019 08:49 AM PST
5 Top NASDAQ Biotech and Pharma Stocks: Atreca Climbs 45 Percent
Dec. 08, 2019 02:55 PM PST
5 Top Pharmaceutical News Stories of 2019
Dec. 05, 2019 12:50 PM PST
TransMedics Announces OCS Technology used in First US Patients
Dec. 04, 2019 09:14 AM PST
Seelos Therapeutics Gets Notice of Allowance for Another US Patent for SLS-005
Dec. 04, 2019 08:59 AM PST
Lixte Biotechnology Enrolls First Patients in LB-100 Study
Dec. 04, 2019 08:44 AM PST
Itamar Medical and SoClean Announce Collaboration
Dec. 04, 2019 08:22 AM PST
Cara Therapeutics Tumbles on Phase 2 Oral KORSUVA Results
Dec. 03, 2019 03:45 PM PST
Cara Therapeutics Announces Results from Phase 2 Trial of KORSUVA
Dec. 03, 2019 09:29 AM PST
Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC
Dec. 03, 2019 09:06 AM PST
MediWound Begins Phase 2 Adaptive Design Study of EscharEx
Dec. 03, 2019 08:51 AM PST